Compare BIO-TECHNE Corp (TECH) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vipshop Holdings Ltd - ADR — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Vipshop Holdings Ltd - ADR trades at $12.52 (market cap $6.20B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.76%). Which is the better fit depends on your goals.
| TECH | VIPS | |
|---|---|---|
Market Cap | $11.34B | $6.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $72.48 | $20.68 |
52-Week Low | $43.31 | $12.51 |
Enterprise Value | $11.36B | $3.02B |
Dividend Yield | 0.44% | 4.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Vipshop Holdings trades at $13.03, down 1.29% with bearish technical signals despite attractive valuation metrics including a P/E of 4.21 and P/S of 0.41. Recent earnings showed mixed results with Q2 2026 missing expectations, while revenue has declined from $112.9B in 2023 to $105.9B in 2025. The company maintains strong profitability with 9.82% net margin and robust cash flow generation.
Analyst consensus remains positive with 54% buy ratings, though near-term headwinds from consumer spending caution and competitive pressures create uncertainty. The stock's deep value proposition is balanced against growth challenges, requiring careful monitoring of Q3 2026 earnings results for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
